Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
Shouksmith AE, Gawel JM, Nawar N, Sina D, Raouf YS, Bukhari S, He L, Johns AE, Manaswiyoungkul P, Olaoye OO, Cabral AD, Sedighi A, de Araujo ED, Gunning PT.
Shouksmith AE, et al. Among authors: johns ae.
ACS Med Chem Lett. 2019 Dec 13;11(1):56-64. doi: 10.1021/acsmedchemlett.9b00471. eCollection 2020 Jan 9.
ACS Med Chem Lett. 2019.
PMID: 31938464
Free PMC article.